# Jaktinib Hydrochloride Cream For Atopic Dermatitis

> **NCT04435392** · PHASE1,PHASE2 · COMPLETED · sponsor: **Suzhou Zelgen Biopharmaceuticals Co.,Ltd** · enrollment: 107 (actual)

## Conditions studied

- Atopic Dermatitis

## Interventions

- **DRUG:** Jaktinib Hydrochloride Cream
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04435392
- **Lead sponsor:** Suzhou Zelgen Biopharmaceuticals Co.,Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-10-14
- **Primary completion:** 2022-09-08
- **Final completion:** 2022-09-08
- **Target enrollment:** 107 (ACTUAL)
- **Last updated:** 2024-04-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04435392

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04435392, "Jaktinib Hydrochloride Cream For Atopic Dermatitis". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04435392. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*